Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Syngene International Ltd. ( (IN:SYNGENE) ) has provided an update.
Syngene International’s board has approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, and recommended a final dividend of Rs 1.25 per equity share for FY 2025-26, with a record date set for 26 June 2026. The board also cleared the appointment of S. R. Batliboi & Associates LLP as statutory auditors for a five-year term starting after the upcoming 33rd AGM on 29 July 2026, and approved managerial remuneration for Executive Chairperson Kiran Mazumdar-Shaw, underscoring continuity in governance and shareholder returns.
More about Syngene International Ltd.
Syngene International Ltd. is an India-based contract research and manufacturing organization operating in the biopharmaceutical and life sciences sector. The company provides discovery, development, and manufacturing services to global pharmaceutical, biotechnology, and other research-driven industries, leveraging its facilities at Biocon Park in Bengaluru.
Average Trading Volume: 162,441
Technical Sentiment Signal: Sell
Current Market Cap: 176.4B INR
For an in-depth examination of SYNGENE stock, go to TipRanks’ Overview page.